Sun Pharmaceutical Industries Ltd
NSE: SUNPHARMA BSE: 524715
₹1752.50
(0.89%)
Wed, 11 Mar 2026, 10:14 am
Market Cap4170.19B
PE Ratio38.52
Dividend0.95
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1983
- Incorporated as partnership firm by Dilip Sanghvi and family in Vapi, Gujarat.
- Converted to public limited company effective March 1.
1994
- Commissioned bulk drug plant at Panoli.
- Commissioned second formulation plant at Silvassa in April.
- Enhanced bulk drugs capacity at Panoli to 92,000 Kgs p.a.
- Enhanced formulation capacity to 1,800 million tablets p.a.
- Proposed modernization of Vapi formulation unit to 1,440 million tablets p.a.
- Proposed additional facilities at SPARC R&D centre.
- Issued 71,85,000 equity shares to promoters.
1995
- Introduced Clofranil SR and Syndopa CR.
- Entered MOU with Knoll Pharmaceuticals for Ahmednagar unit.
- Allotted 35,92,500 bonus shares in 1:2 ratio.
- Issued 3,23,400 rights shares at premium of Rs 130.
- Issued 37,00,300 equity shares at premium of Rs 140 to public.
1996
- Launched 18 new products and 4 line extensions.
- Acquired controlling stake in MJ Pharmaceuticals.
- Signed MoU with Shah family for MJPL shareholding.
1997
- Acquired 78,36,000 equity shares.
- Merged Tamil Nadu Dadha Pharmaceuticals effective April 1 in 4:1 ratio.
- Allotted 4,13,633 equity shares to erstwhile TDPL shareholders.
- Approved 1:4 swap ratio for TDPL merger.
- Set up Sun Pharma Advanced Research Centre (SPARC) in Vadodara.
- Planned new tablet manufacturing facility at Silvassa.
1998
- Launched Duracard for blood pressure and cholesterol.
- Launched Cardivas for heart failure.
- Launched Muvera anti-inflammatory and Octapeptide Octride.
- Allotted 2,08,000 shares to shareholders of Milment Labs pursuant to amalgamation.
- Converted Sun Pharma Exports into 100% subsidiary.
1999
- Planned pharmaceutical plant in Bangladesh under joint venture.
- Hived off Sun Pharmaceutical Exports into 100% subsidiary.
2000
- Merged wholly owned subsidiary Sun Pharma Exports.
- Allotted 3,08,44,466 bonus equity shares in 2:1 ratio.
- Launched Edegra (Sildenafil) in 25, 50, 100 mg.
- Introduced products including Celact, Oleanz, Rofact, Nodict, Fexotrol, Zelast, Ketorid.
- Merged 99.28% subsidiary Sun Pharmaceuticals Exports.
2001
- Approved merger of Pradeep Drug Company.
- Approved merger of Sun Pharmaceutical Advanced Research Centre.
- Launched 33 new products across speciality divisions.
- Ranked 5th by domestic prescription product sales; rated among best 200 global companies by Forbes.
2002
- Caraco received US FDA preliminary approval for metformin hydrochloride.
- Shareholders approved merger with Pradeep Drug Company effective April 1, 2000.
- Made open offer to purchase shares at Rs 600 per share.
- Launched Lupride Depot IM for prostate cancer.
- Inducted Keki Mistry to board of directors.
- Allotted 18,71,77,232 6% Cumulative Redeemable Preference Shares as bonus.
2003
- Announced buyback of up to 2,000,000 equity shares.
- Accepted resignation of R K Baheti; appointed Kamlesh H Shah as Company Secretary.
- Caraco received US FDA approval for generic Digoxin.
- Redeemed 1,42,99,833 6% Cumulative Redeemable Preference Shares.
- Extinguished 3,01,20,608 Preference Shares.
- Board approved closure of share buyback.
- Delisted equity shares from Vadodara Stock Exchange.
2004
- Acquired common stock and options in Caraco, increasing stake to over 60%.
- Halol formulation site received approvals from USFDA, UK MHRA, others.
- Two API factories received USFDA approval.
- Acquired Phlox Pharma, cephalosporin actives manufacturer.
- Acquired niche brands Ortho-Est and Midrin from Women's First Healthcare.
- Ranked by Forbes Global among most valuable companies (turnover < $2 billion).
2005
- Acquired plant in Bryan, Ohio, US and ICN Hungary business from Valeant Pharma.
- Acquired intellectual property and assets of Able Labs from US bankruptcy court.
- Dilip Sanghvi received E&Y Entrepreneur of the Year award in healthcare.
- Selected by Forbes as one of best 200 companies in Asia (sales < USD 1 billion).
- Shifted registered office to SPARC, Tandalja, Vadodara.
2006
- Announced demerger of innovative business into new company.
2007
- Completed demerger of innovative business into SPARC Ltd., listed on Indian stock exchanges.
- Signed agreements to acquire Taro Pharmaceutical Industries for $454 million.
2008
- Launched generic Pantoprazole Sodium DR Tablets 40 mg in the US.
- Acquired 100% ownership of Chattem Chemicals.
2010
- Completed acquisition of controlling stake in Taro Pharmaceutical Industries.
- Won court victory in battle to acquire Taro Pharmaceuticals.
- Launched generic Exelon in US.
- Supreme Court of Israel ruled in favor of Sun Pharma.
- Split face value of shares from Rs 5 to Re 1.
2011
- Established joint venture with Merck & Co. to develop and commercialize novel formulations in emerging markets.
- Entered strategic partnership with MSD in India to co-market diabetes drug.
2012
- Received USFDA approval for generic Zyprexa.
- Israel Makov appointed Chairman of Sun Pharma Board.
- Acquired URL generic business from Takeda.
- Promoters emerged as new JV partner for Telenor operations in India.
2013
- Received US FDA approval for generic Cymbalta.
- Formed joint venture with Intrexon for therapeutics for ocular diseases.
- Received USFDA approval for generic Prevacid.
- Received USFDA approval for generic Depo-Testosterone Injection.
- Announced 1:1 bonus issue.
- Received tentative USFDA approval for generic Januvia and Glumetza.
- Received USFDA approval for generic Doxil.
2014
- Received US FDA approval for generic Temodar.
- Acquired Pharmalucence.
- Entered licensing agreement with Merck & Co. for Tildrakizumab.
- Announced acquisition of Ranbaxy for US$4 billion.
2015
- Received US FTC clearance for Ranbaxy acquisition.
- Entered distribution agreement with AstraZeneca for ticagrelor in India.
- SPARC licensed Xelpros (Latanoprost BAK-free) to Sun Pharma.
- High Court of Gujarat approved amalgamation of Sun Pharma Global Inc.
- Received US FDA approval for Ximino.
- Completed acquisition of Opiates business in Australia.
- Announced Absorica patent litigation settlement.
- Acquired Insite Vision.
2016
- Received CCI approval for CNS deal.
- Launched Imatinib Mesylate in the US.
- Acquired Novartis brands for Rs 1,900 crore.
- Received USFDA approval for BromSite.
- Signed exclusive agreement with ICGEB for novel botanical drug for Dengue.
- Launched sunscreen brand Suncros.
- Launched Gemcitabine InfuSMART in Europe.
- Received approval for generic Glumetza.
- Completed acquisition of Ocular Technologies.
- Completed acquisition of 85% stake in JSC Biosintez.
2017
- FDEC commenced roll-out of Malaria demonstration project.
- Subsidiary received approval for new label for Odomzo.
- Received EIR for Dadra formulation facility.
2018
- Launched Kapspargo Sprinkle in the US.
- Received CSR award from FGI.
2019
- Launched Drizalma Sprinkle in the US.
- Launched Ready-to-Infuse INFUGEM in the US.
2020
- Launched FluGuard (Favipiravir) in India at Rs. 35 per tablet.
- Introduced ABSORICA LD Capsules for severe recalcitrant nodular acne in the US.
2021
- Launched website for Long Term Care Portfolio in the US.
- Launched Sunkalp on National Doctors' Day.
- Launched Chericof 12 in India for 12-hour cough relief.
2022
- Entered license agreement with SPARC for commercialization of phenobarbital for injection in the US.
- Expanded license and supply agreements with Cosmo for WINLEVI to include Japan.
- Launched CEQUA, first dry eye treatment with nanomicellar technology, in Canada.
- Obtained exclusive patent license from Lundbeck to introduce Vortioxetine in India.
- Acquired Uractiv Portfolio from Fiterman Pharma in Romania.
2023
- Entered licensing agreement with Zydus for co-marketing Desidustat in India.
- US FDA accepted NDA filing for Deuruxolitinib.
- Sun Pharma Canada launched PR WINLEVI (clascoterone cream 1% w/w) for acne.
- Entered licensing agreement with Pharmazz Inc. for Tyvalzi (Sovateltide) in India.
- Launched nationwide initiative Second Birth Date on National Doctor’s Day.
2024
- Entered global exclusive commercialization, license, and supply agreement with Philogen for FIBROMUN.
- Completed acquisition of all outstanding shares of Taro.
- Included in S&P Global Sustainability Yearbook.
- Launched STARIZO (Tedizolid Phosphate) in India for acute bacterial skin and skin structure infections.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800